



Effective glucose metabolism maintains low intracellular glucose in airway epithelial 4 
cells after exposure to hyperglycaemia. 5 
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Running Title: Glucose metabolism in airway epithelial cells 25 
 26 
Abstract 27 
The airway epithelium maintains differential glucose concentrations between the airway 28 
surface liquid (ASL, ~0.4mM) and the blood/interstitium (5-6mM) which is important for 29 
defence against infection. Glucose primarily moves from the blood to the ASL via 30 
paracellular movement, down its concentration gradient, across the tight junctions. However, 31 
there is evidence that glucose can move transcellularly across epithelial cells. Using a Förster 32 
Resonance Energy Transfer (FRET) sensor for glucose, we investigated intracellular glucose 33 
concentrations in airway epithelial cells and the role of hexokinases in regulating intracellular 34 
glucose concentrations in normo- and hyperglycaemic conditions.  Our findings indicated that 35 
in airway epithelial cells (H441 or primary human epithelial cells HBEC) exposed to 5mM 36 
glucose (normoglycaemia), intracellular glucose concentration is in the μM range.  Inhibition 37 
of facilitative glucose transport (GLUT) with Cytochalasin B reduced intracellular glucose 38 
concentration.  When cells were exposed to 15mM glucose (hyperglycaemia), intracellular 39 
glucose concentration reduced.  Airway cells expressed hexokinases I, II and III. Inhibition 40 
with 3-bromopyruvate decreased hexokinase activity by 25% and elevated intracellular 41 
glucose concentration but levels remained in the μM range.  Exposure to hyperglycaemia 42 
increased glycolysis, glycogen and sorbitol.  Thus, glucose enters the airway cell via GLUT 43 
transporters and is then rapidly processed by hexokinase-dependent and hexokinase 44 
independent metabolic pathways to maintain low intracellular glucose concentrations.  We 45 
propose this prevents transcellular transport, aids the removal of glucose from the ASL and 46 







Glucose concentrations in the airway surface liquid (ASL) of a healthy individual are 54 
typically 0.4mM; 12.5x lower than plasma glucose concentrations (5mM), but this has been 55 
shown to rise during periods of hyperglycaemia and inflammation (1, 31). Previous studies 56 
have shown that the appearance of glucose in the ASL is largely reliant on paracellular 57 
movement of glucose via tight junctions, down its concentration gradient (19, 30). However, 58 
there is some evidence that glucose can also move transcellularly across the airway 59 
epithelium from the blood to the ASL via glucose transporters in the cellular membrane (19, 60 
22, 30).  Such a process is found in other systems such as the intestine and the kidney (where 61 
glucose moves from the lumen to the blood) although the gradient driving transcellular 62 
movement of glucose in these tissues is in the opposing direction to that of the lung (16, 27). 63 
We hypothesised that transcellular movement of glucose in the airway is largely dependent 64 
on the intracellular concentration of glucose which is regulated by hexokinase activity. Low 65 
intracellular glucose maintains a driving force for glucose to enter the cell. However, if 66 
intracellular glucose concentrations rise to that of ASL or higher, for example during 67 
exposure to hyperglycaemia, this would promote luminal efflux of glucose. Understanding 68 
the routes for glucose movement across the airway epithelium is vital because an increase of 69 
glucose in the ASL has been associated with increased airway infections in respiratory 70 
disease (3, 5).  71 
 72 
Glucose Förster Resonance Energy Transfer (FRET) sensors have been developed to exhibit 73 
a change in fluorescence output upon glucose binding, indicating a change in local glucose 74 
concentrations. These sensors have been used to measure intracellular glucose concentrations 75 
in systems such as ovarian epithelial cells (4) and glucose fluxes in pancreatic β cells (21). To 76 
our knowledge, intracellular glucose concentrations in airway epithelial cells and the 77 
metabolic processes regulating intracellular glucose concentrations have not yet been 78 
investigated.  79 
 80 
In this study, we used a FRET sensor to measure intracellular glucose concentrations in 81 
airway epithelial cells in normo- and hyper-glycaemic conditions. We also investigated the 82 
involvement of hexokinases in regulating intracellular glucose concentration, airway cell 83 
glucose metabolism and the effect on ASL glucose concentrations.  84 
 85 
 86 
Materials and methods 87 
      Cell culture 88
H441 airway epithelial cells were cultured at 37⁰C, 5% CO2 in RPMI 1640 media containing 89 
10mM glucose and supplemented with 10% Foetal calf serum (Sigma Aldrich, USA), 2mM 90 
L-glutamine, 1mM Sodium pyruvate, 5µg/ml insulin, 2.75µg/ml penicillin and 100mg/ml 91 
streptomycin (Life Technologies, USA). Human bronchial epithelial cells HBEC cells were 92 
originally purchased from Lonza and Epithelix SàRL prior to semi-immortalization with 93 
BMI-1 transduction and were cultured in collagen coated flasks (Corning) in bronchial 94 
epithelial growth media (BEGM; Lonza) in a humidified environment at 37⁰C, 5% CO2. 95 
Growth media was replaced every second day, and cells were passaged once 80% confluent.  96 
 97 
Polarised monolayers were cultured on Transwells (Corning, USA). H441 cells were plated 98 
onto the Transwell using the medium described above until confluent.  The apical medium 99 
was then removed and the basolateral medium was changed to RPMI 1640 media containing 100 
10mM glucose and supplemented with 4% charcoal stripped serum, 200µM dexamethasone, 101 
10nM 3,3’-5-triiodothyronine, 2mM L-glutamine, 1mM sodium pyruvate, 5µg/ml insulin, 102 
2.75µg/ml penicillin and 100mg/ml streptomycin. Cells were then cultured at air-liquid 103 
interface (ALI) for 10 days, changing the medium every other day until they formed a 104 
resistive monolayer. HBEC were seeded at a density of 200,000 cells cm-2 on Transwells. 105 
After confluence was achieved, media was removed from the apical surface and the cells 106 
were fed on the basolateral side only with 50% BEGM and 50% Hi-glucose minimal essential 107 
medium containing 100 nM retinoic acid. The media was exchanged every 2 to 3 days and 108 
the apical surface mucus was removed by gentle washing with phosphate-buffered saline 109 
once a week. Cultures were used for functional analysis 28-35 days after exposure to ALI. 110 
BMI-1 transduced cells exhibit normal cell morphology, karyotype, and doubling times 111 
despite extensive passaging. When cultured at ALI they show normal ciliation, production of 112 
MUC5AC, MUC5B and have electrophysiological properties similar to primary cells (26). 113 
Transepithelial resistance was measured before use with an epithelial volt/ohm meter EVOM 114 
(Word Precision Instruments) and at least 200 Ωcm2 was required before use in experiments. 115 
18 hours prior to experiments, cell media was exchanged with growth medium containing 116 
5mM D-glucose (supplemented as listed above). To investigate the effect of hyperglycaemia, 117 
cells were either exposed to 5mM D-glucose + 10 mM L-glucose (an analogue not 118 
transported or metabolised to control for any osmotic effects of raising glucose), to mimic 119 
normoglycaemia (5mM glucose) or 15 mM D-glucose to mimic hyperglycaemia (15 mM 120 
glucose) -. The apical surface of cell cultures were gently washed with 100μl PBS to obtain 121 
airway surface liquid washes.  Glucose in the washes was analysed using an amplex red 122 
glucose oxidase kit (ThermoFisher, UK). 123 
 124 
Cell Transfection 125 
Cells were seeded at a density of 2x105 onto glass coverslips coated in poly-lysine and once 126 
at 50-65% confluency, were transiently transfected with 1µg of the glucose sensitive sensor 127 
FLII12Pglu-700µΔ6 (Addgene plasmid # 17866) or CFP-YFP FRET positive control plasmid 128 
(a kind gift from R. Tarran UNC, Chapel Hill15) using Lipofectamine 2000 (Thermo Fisher, 129 
UK). Polarised monolayers were apically transfected in a similar fashion, with 1µg of 130 
plasmid transfected using TransIT-X2 (Mirus, USA) applied to the apical surface of the cells.  131 
 132 
FRET microscopy 133 
Cells were imaged 48-72 hours post transfection in phosphate buffered saline at 37°C, 95% 134 
air/ 5% CO2, supplemented with glucose and/or inhibitors using a Zeiss LSM 510 Meta 135 
confocal microscope with a 20x Pan-Neofluar lens, or a Leica SP8 with a 20x PL APO CS2 136 
lens. FLII12Pglu-700µΔ6 contains the FRET paired fluorophores eCFP (donor) and citrine 137 
(acceptor) which reports a reduced eCFP/citrine FRET ratio with a binding of glucose. This 138 
was measured on the Zeiss LSM 510 by collecting emission data from eCFP (459-505nm) 139 
and citrine (525-600nm) every 4 seconds over an 8-minute time period whilst exciting eCFP 140 
at 458nm.  Settings were optimised for the growth conditions of each cell type which took 141 
into account opacity of the substrate (ie glass coverslips, Transwells), cell height and density.  142 
Thus, the output measurement was different for the three conditions studied.  143 
 144 
Generating dose response data for the sensor 145 
Glucose dose response data was generated for each cell type and growth condition. Cells 146 
transfected with FLII12Pglu-700µΔ6 were treated with hexokinase inhibitor 3-Bromopyruvic 147 
acid (BrPy) (100µM) plus the respiratory chain complex I inhibitor, Rotenone (100nM) for 148 
30 minutes to inhibit glucose metabolism. During this time cells were incubated with 149 
different glucose concentrations to equilibrate intracellular glucose with extracellular glucose 150 
prior to imaging as previously described to equilibrate intracellular and extracellular lactate 151 
for FRET measurement (33). FRET activity of FLII12Pglu-700µΔ6 was imaged as described 152 
above. 153 
Hexokinase assay 154 
Cells were untreated or pre-treated for 10 minutes with BrPy (0.1µM-1mM) at 37°C, 95% 155 
air/5% CO2. Cell lysates were prepared and a colorimetric hexokinase assay (ab136957, 156 
Abcam, UK), which measures the conversion of glucose to glucose-6-phosphate by 157 
hexokinase, was performed as per the manufacturer’s instructions.  158 
 159 
Sorbitol assay  160 
Proliferating H441 cells were exposed to 5mM D- + 10mM L- glucose or 15mM D-glucose 161 
in the presence or absence of BrPy (100µM) for 10 minutes prior to washing in ice-cold PBS. 162 
Cells were then lysed in 200µl of assay buffer and centrifuged for 5 minutes at 4°C at 163 
12,000rpm. The lysate was decanted, and sorbitol concentrations were determined by sorbitol 164 
colourimetric assay (Abcam, ab118968) as per the manufacturer’s protocol.  165 
 166 
Seahorse Glycolysis Stress Assay 167 
Human bronchiolar epithelial cells were seeded into a Seahorse XF96 plate and incubated at 168 
37°C, 5% CO2 for 48 hours. The medium was changed 24 hours prior to Seahorse 169 
experiment and cells were exposed to 5 or 15 mM glucose with or without BrPy (100μM) or 170 
Epalrestat (1 or 10μM) for the last 30 minutes before the Seahorse Glycolysis Stress Assay 171 
was performed according to the manufacturer’s instructions followed by the sequential 172 
injection of oligomycin to inhibit ATP-linked reparation and 2-Deoxy-D-Glucose (2-DG) to 173 
inhibit glucose metabolism. The plate layout was separated into quadrants to reduce edge 174 
effects. Extracellular acidification rate (ECAR) and oxygen consumption rate (OCAR) were 175 
measured. Glycolysis rate was calculated by subtracting the normalized ECAR values after 2-176 
DG injection from the ECAR values after glucose injection in order to exclude the non-177 
glycolytic acidification from the calculation. Glycolytic capacity was calculated by 178 
subtracting the non-glycolytic acidification rate (ECAR after 2-DG injection) from the 179 
maximum ECAR after 1 μM oligomycin injection. 180 
 181 
Western Blots 182 
Cells were lysed in RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA  183 
1 mM EGTA, 1% NP-40, 1% sodium deoxycholate) plus protease inhibitor cocktail (Sigma, 184 
UK) with gentle agitation at 4°C, 30 minutes. Protein concentration was calculated from a 185 
BCA assay (Thermo Fisher, UK). 20µg of protein was electrophoresed through a 4-12% Bis-186 
Tris gel. Gels were blotted onto a PVDF membrane and blocked with Odyssey blocking 187 
buffer (LiCor, USA). Membranes were incubated in primary antibodies (Hexokinase I: 188 
ab65069; 1:500, Hexokinase II: ab37593; 1:250, Hexokinase III: ab126217; 1:500, B-Actin: 189 
A5441, 1:10000) followed by secondary antibodies (goat-anti-rabbit 680RD: 925-68071, 190 
1:15000 and donkey-anti-mouse 800CW, 925-32212, 1:15000). Blots were imaged using the 191 
LiCor Odyssey system. 192 
 193 
Data analysis 194 
FRET eCFP/citrine intensity and western blot band intensity data was measured using ImageJ 195 
software. Data are displayed as mean values ± standard deviation and analysed using 196 
GraphPad prism 7 using ANOVA followed by a post hoc Tukeys test unless otherwise stated. 197 
 198 
Results 199 
Hexokinase proteins I, II and III are present in airway epithelial cells 200 
As glucose enters the cell it is phosphorylated by hexokinases to glucose-6-phosphate 201 
reducing the intracellular concentration of free glucose.  Western blot of cell extracts from 202 
H441 cells grown on plastic (proliferating) or H441 and HBEC grown at air-liquid interface 203 
indicated the presence of hexokinases I, II and III in these cells.  There was no observed 204 
difference in the total cellular abundance (hexokinase/actin) of these proteins in H441 cells 205 
after exposure to either 5mM or 15 mM glucose (Figure 1A&B). 206 
 207 
Hexokinase activity in airway cells is reduced by BrPy 208 
Addition of BrPy to H441 cells reduced total hexokinase activity in cell extracts in a dose 209 
dependant manner with an IC50 of 1.2±0.28 mM (Figure 2A).  The data did not follow a 210 
classic sigmoid curve and there was an indication that the inhibition was biphasic. We were 211 
unable to unambiguously fit such a curve to the data. However, the IC50 obtained from the 212 
initial inhibition of hexokinase activity was lower at 0.04±0.01mM.  As there was no 213 
statistical difference in hexokinase activity between pre-treatment with 100µM or 1mM, it 214 
was decided to use the lower concentration of BrPy. At this concentration total cellular 215 
hexokinase activity was reduced by 25.1 ± 11.6 % in H441 cells cultured at air-liquid 216 
interface (n=6) (Figure 2B).  217 
 218 
Hexokinse activity drives glycolysis in airway cells 219 
Using the seahorse assay, we previously showed that airway cells produce energy by 220 
mitochondrial respiration (OCR) and that elevation of extracellular glucose shifts metabolism 221 
to glycolysis (ECAR) which is associated with increased lactic acid secretion (12). We found 222 
that BrPy (100μM) was effective at inhibiting both mitochondrial respiration (Figure 3A) and 223 
glycolysis in these cells (Figure 3B&C).  We calculated that BrPy inhibited glycolysis with 224 
an IC50 of 0.06 ± 0.02 mM (Figure 3D). Application of 2-DG, an inhibitor of all hexokinase 225 
activity was more effective at inhibiting respiration and glycolysis (Figures 3A,B,C)  These 226 
data indicate that glycolysis is predominantly driven by hexokinase II activity in these cells. 227 
 228 
Elevating extracellular glucose and inhibiting hexokinase activity changed FRET ratio 229 
in non-polarised, polarised H441 and HBEC.  230 
Proliferating H441 cells transfected with FLII12Pglu-700µΔ6 and exposed to 5mM 231 
extracellular glucose, exhibited a cyclic fluctuation in FRET ratio of eCFP/citrine over time, 232 
with a full cycle taking 3.4 ± 0.2 minutes (n=16) (Figure 4A).  This was not observed when 233 
the control FRET eCFP/citrine plasmid was transfected into cells (data not shown). Elevation 234 
of extracellular glucose to 15 mM resulted in an increase in FRET ratio from 1.54 ± 0.02 to 235 
1.6 ± 0.02 (p<0.0001, n=117), indicating a decrease in intracellular glucose.  In addition, the 236 
cyclic fluctuations slowed to 4.3 ± 0.3 minutes for a full cycle (n=16; p<0.05) Figure 4A.  237 
Pre-treatment with the hexokinase inhibitor BrPy decreased FRET from 1.54 ± 0.02 to 1.41 ± 238 
0.01 (p<0.0001; n=117) indicating that intracellular glucose was increased (Figure 4A). 239 
Furthermore, BrPy prevented the large cyclic fluctuations in FRET indicating that hexokinase 240 
activity was associated with this phenomenon. As an alkylating agent, it is possible that BrPy 241 
could directly affect the sensor. However, this would likely reduce glucose binding or 242 
stochiomic changes to the sensor, neither of which would explain these results.  Thus, these 243 
data indicate that intracellular glucose concentration fluctuated with external glucose 244 
concentration and hexokinase activity. 245 
 246 
H441 cells cultured at air-liquid interface on permeable supports required altered microscope 247 
conditions for FRET acquisition which meant that the measured FRET ratio of eCFP/citrine 248 
was decreased compared to that observed in proliferating cells.  Nevertheless, in cells 249 
exposed to 5mM extracellular glucose the pattern of response was similar to that seen in 250 
proliferating cells.  A cyclic fluctuation in FRET ratio was also observed in these cells with a 251 
full cycle taking 4.4 ± 0.6 minutes, in 5mM glucose.  Elevation of extracellular glucose to 252 
15mM resulted in an increased FRET ratio from 0.38 ± 0.007 to 0.41 ± 0.005 (p<0.0001, 253 
n=83) Addition of BrPy reduced FRET ratio to 0.34 ± 0.003 and the cycling frequency to 1.3 254 
± 0.23 minutes (p≤0.001; n=16).  255 
 256 
Optimisation of FRET acquisition in HBEC cultured at air-liquid interface also resulted in a 257 
change in FRET ratios obtained.  However, similar to H441 cells, FRET ratio increased when 258 
extracellular glucose was increased from 5mM to 15mM (p<0.0001, n=149). 259 
 260 
Inhibition of GLUT mediated glucose uptake increased FRET ratio in H441 cells grown 261 
at air-liquid interface.  262 
Cytochalacin B is molecule larger than glucose, which binds to the pore of facilitative 263 
glucose transporters (GLUT) and blocks glucose uptake.  Cytochalacin B treatment of H441 264 
cells grown at air-liquid interface and exposed to 5mM or 15mM glucose significantly 265 
increased FRET ratio (p<0.0001, n=24 respectively).  These data indicate that inhibition of 266 
glucose uptake into the cell reduced intracellular glucose (Figure 5). 267 
  268 
Intracellular glucose concentration of H441 and HBEC. 269 
A dose response curve for FRET ratio was generated for the three different cell/growth 270 
conditions using the individual imaging conditions used.  An exemplar dose response curve 271 
for proliferating H441 cells is shown (Figure 4B). This was then used to interpolate the data 272 
points shown in Figure 4A to calculate the intracellular concentration of glucose. The mean 273 
intracellular glucose concentration for proliferating H441 cells in 5mM glucose was 0.23 ± 274 
0.05mM. Raising the glucose concentration to 15mM glucose resulted in a decrease in 275 
intracellular glucose to 0.05 ± 0.04 mM.  Pretreatment with BrPy increased intracellular 276 
glucose concentration to 0.49 ± 0.01 mM in 5mM  and  0.46  ±  0.03 in 15 mM glucose 277 
(p<0.0001, n=117 compared to control respectively) (Figure 6A).  278 
 279 
Interpolation of data from H441 cells cultured at air-liquid interface indicated that these cells 280 
has a mean intracellular glucose of 0.36 ± 0.005 mM in 5mM basolateral glucose and this 281 
decreased to 0.26 ± 0.003 mM when basolateral glucose was increased to 15mM. Addition of 282 
BrPy in the presence of 5mM basolateral glucose increased intracellular glucose 283 
concentration to 0.72 ± 0.003 mM (p≤0.0001; n=83) (Figure 6B).  284 
 285 
A similar pattern was seen in HBEC grown at air-liquid interface. Intracellular glucose 286 
concentration was 0.09 ± 0.002 mM in 5mM glucose and this decreased to 0.03 ± 0.001 mM  287 
when basolateral glucose concentration was raised to 15 mM (n=150) (Figure 6C).  288 
 289 
Glucose metabolism 290 
Glycolysis was increased in HBEC in response to elevation of extracellular glucose 291 
concentration from 5mM to 15mM consistent with our previous observations in H441 cells 292 
(Figure 7A) (12).   In addition, the amount of glycogen per culture was increased two fold 293 
after exposure to 15mM glucose (from 9.1±1.3 to 20.2±1.5 mg/ml, p<0.0001, n=6).  294 
Inhibition of hexokinase with BrPy (100µM) reduced glycogen in H441 exposed to 15mM 295 
(p<0.001, n=6) but not 5mM glucose (Figure 7B). Thus, elevation of extracellular glucose 296 
increased hexokinase driven glycolysis and glycogen synthesis. 297 
 298 
Hexokinase-independent pathways are also present in airway cells, such as the polyol 299 
pathway, which utilises aldose reductase to convert glucose to sorbitol. Such a pathway could 300 
also contribute to maintaining low intracellular glucose in the face of increased extracellular 301 
glucose.  There was no significant difference in mean intracellular sorbitol between cells 302 
grown in 5 or 15 mM glucose.  However, inhibition of hexokinase activity with BrPy in the 303 
presence of 15mM glucose caused a small but significant elevation of sorbitol (from 304 
0.04±0.001 to 0.05±0.002, p<0.01, n=8). This elevation was inhibited by the aldose reductase 305 
inhibitor epalrestat (30μM) (n=8) (Figure 7C). These data indicate that under circumstances 306 
when intracellular glucose rises, the sorbitol pathway can contribute to glucose utilisation in 307 
these cells. 308 
 309 
Airway surface liquid glucose 310 
Glucose in washes from the ASL of cell cultures grown at air-liquid interface were increased 311 
from 3.6±0.7 to 45.2±1.7 μM, p<0.001, n=4 and 7 respectively) when basolateral glucose 312 
was raised from 5 to 15 mM for 6 hours.  Taking into account the original volume of ASL, 313 
these values approximate to 0.5mM and 6mM respectively, similar to previously published 314 
values (12). Treatment with BrPy had no further effect on ASL glucose concentrations.  315 




Both H441 and primary HBEC expressed all three isoforms of hexokinase (HKI, II and III).  320 
This finding was consistent with that described for lung tissue but now further localises these 321 
isoforms to airway epithelial cells (24). HKI is found in most cells and is thought to be the 322 
key enzyme driving oxidative phosphorylation and the production of ATP whereas HKII is 323 
thought to be more limited in its expression and associated with insulin–sensitive tissues (9). 324 
HKIII is associated with the cytosol and nuclear periphery (32). We found that growth at air-325 
liquid interface or elevation of glucose from 5-15 mM had no effect on the observed 326 
abundance of any of the individual isoforms consistent with the finding that HKI, II and III 327 
did not change in the lungs of alloxan–induced diabetic rats compared to wild type (24).  328 
Furthermore, we did not observe any difference in total cellular abundance of HKII in H441 329 
cells (derived from a papillary adenocarcinoma) compared to HBEC, although it is widely 330 
accepted to be upregulated in non-small cell lung cancers (23).   331 
HKII is a key enzyme controlling anabolic (glycogen synthesis) and catabolic (glycolysis) 332 
pathways in the cell.  In muscle cells, it shuttles to the mitochondria in response to elevated 333 
extracellular glucose driving glycolysis and glycogen storage (6, 17). The pyruvate mimetic 334 
BrPy enters the cell via MCT transporters (present in H441 cells and HBEC (12)) and is a 335 
potent inhibitor of glycolysis (7, 8, 34).  It is reported to decrease HKII activity by alkylating 336 
and dissociating the enzyme from the mitochondrial membrane (7, 8, 34). HKI is also 337 
associated with the mitochondrial membrane and is proposed to maintain glycolysis when 338 
extracellular glucose levels are low (17). We could find no evidence to support an effect of 339 
BrPy on this hexokinase (17).  As HKIII is not bound to the mitochondria, BrPy likely has no 340 
effect on this isoform. Our finding that BrPy only inhibited 25% of total hexokinase activity 341 
(HKI, II and III) in cell extracts would indicate that it predominantly targeted HKII activity in 342 
these cells but that total cellular hexokinase activity includes that of HKI and HKIII.  The 343 
concentration effect curve for BrPy also indicated a possibility that BrPy inhibited two 344 
hexokinases with differing affinities. The initial inhibition (ie that potentially attributable to 345 
HKII) had an IC50 of approximately 40μM. BrPy inhibited glycolysis with a similar IC50 of 346 
60 μM. Others have found similar concentrations of BrPy to inhibit glycolysis in other cell 347 
types and this has been attributed to inhibition of HKII (10, 15, 29)  348 
 349 
We used the intracellular FRET sensor FLII12Pglu-700µΔ6 because the purified sensor was 350 
largely unaffected by pH, had the lowest Kd (660 mM) and the highest dynamic range to 351 
ascertain whether intracellular glucose could reach levels higher than that detected in ASL 352 
(~400μM)(35). The standard curve we obtained from the sensor expressed in airway cells had 353 
a similar Kd. Whilst we recognise that the measurement of intracellular glucose concentration 354 
below 100μM were towards the limit of detection with this sensor, we found that intracellular 355 
glucose concentrations were in the μM range in all our cell models. In HBEC cells grown at 356 
air-liquid interface, values were below or equivalent to concentrations we found in the airway 357 
surface liquid (~0.4 mM) in vivo and in vitro (3, 13, 37).  These findings support our previous 358 
proposal that to maintain ASL glucose concentrations at this level, airway epithelial cell 359 
intracellular glucose must be similar or lower to drive glucose uptake (11, 13). We did not 360 
take the pulsed approach to changing external glucose for FRET analysis and we found that 361 
whilst there were consistent overall changes in FRET output, we also observed cyclic 362 
fluctuations in intracellular glucose that were inhibited by BrPy (18). As generation of 363 
glucose-6-phosphate by hexokinases inhibits HKII activity with high affinity (17) we suggest 364 
that this phenomenon underpins these changes (28, 36).   365 
 366 
Cytochalacin B, which is reported to inhibit glucose transport via GLUT1, 2, 3 and 4, 367 
decreased intracellular glucose (2). Inhibition of GLUT 1 and 9 by siRNA in hepatocytes had 368 
a similar effect (35). We and others previously proposed that glucose uptake in airway cells 369 
utilised GLUT1, 2, 4 and 10 (19, 20, 25, 30).  As the effect of Cytochalasin B on GLUT10 is 370 
currently unknown, we suggest that glucose moves into the airway epithelial cell at least via 371 
GLUT1/2/4 and rapid metabolism by HKII maintains low intracellular glucose. 372 
 373 
A surprising finding of the study was that intracellular glucose decreased with extracellular 374 
hyperglycaemia.  This was associated with an increase in glycolysis (12) consistent with our 375 
previous observations, glycogen synthesis and potentially other glucose utilisation pathways 376 
such as the polyol pathway. Interestingly, glycogen synthase was stimulated by 377 
hyperglycaemia in myoblasts but only when glycogen stores were depleted. The calculated 378 
glycogen content in our cells was approximately 10x lower that reported for glucose-starved 379 
myoblasts. Thus, it is possible that hyperglycaemia also stimulates glycogen synthase in 380 
airway cells (14). BrPy increased intracellular glucose concentration. As HKII was reported 381 
to respond rapidly to changes in external glucose we propose that HKII is key in directing the 382 
fate of glucose in these cells (17).  However, intracellular concentration of glucose remained 383 
low in comparison to the external glucose concentration.  This, together with the finding that 384 
only 25% of cellular hexokinase activity was inhibited by BrPy indicates roles for hexokinase 385 
I and III in maintaining low intracellular glucose concentration in airway cells.  386 
 387 
Effective metabolism and low intracellular glucose in airway cells provides a driving force 388 
for glucose uptake. We propose that this helps reduce transepithelial glucose concentration 389 
gradients and aids clearance of glucose from the ASL via glucose transporters in the 390 
basolateral and apical membranes (19, 20).  This work focused on short term changes in 391 
extracellular glucose concentration.  We have not yet investigated the effect of chronic 392 
elevation of glucose (as observed in poorly controlled diabetes) or in lung disease conditions 393 
such as Cystic Fibrosis where glucose metabolism is reportedly compromised (25).  394 
Nevertheless, these data support our proposal that during hyperglycaemia, glucose 395 
predominantly moves across the epithelium into the ASL via the paracellular rather than 396 
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Figure legends 515 
 516 
Figure 1. H441 cells and HBEC express all three forms of hexokinase. Representative 517 
western blots of cell lysates from H441 cells grown on plastic (panel A) or H441 cells or 518 
HBEC grown at air-liquid interface (panel B). Lanes indicate cell type and growth conditions 519 
of either 5mM) or 15mM glucose as indicated. Proteins immunostained for Hexokinases I, II 520 
and III are indicated to the right of the blots (all approximately ~100kDa).  The 521 
immunostained housekeeping protein, β-actin is also indicated (Actin) and serves as a 522 
loading control. 523 
 524 
Figure 2. Hexokinase activity is inhibited by BrPy. A. Effect of 3-bromopyruvate 525 
concentration on hexokinase activity in cell extracts from H441 cells exposed to 5mM 526 
glucose. The dose response did not follow a classic sigmoid curve and there was an indication 527 
that the inhibition was biphasic. Two curves could be fitted to the data to reflect initial 528 
inhibition (left hand curve) with an IC50 of 0.04±0.01mM or overall inhibition (right hand 529 
side) with an IC50 of IC50 of 1.2±0.28 mM (n=4). B. Total hexokinase activit 530 
y in cell extracts from control (black bar) or BrPy100μM treated cells (grey bar). Individual 531 
data points are shown with mean ± SD, **** Significantly different from control P<0.0001. 532 
 533 
Figure 3. BrPy inhibits glycolysis in airway epithelial cells. 534 
Seahorse metabolic assay of airway cells exposed to medium or different concentrations of 535 
BrPy (1μM-1mM) as indicated to right hand side of graphs.  A. Oxygen consumption rate 536 
(OCR), B extracellular acidification rate (ECAR), C. ECAR/OCR before and after injection 537 
of 5mM glucose, oligomycin or 2-DG at points indicated.  D. Dose response of glycolysis to 538 
BrPy was fit with a sigmoidal curve (Df 25, r2 0.95) with an IC50 of 0.06 ± 0.02 mM.  539 
 540 
Figure 4. FRET ratio (ECFP/Citrine) was measured over a period of 6 minutes using the 541 
glucose FRET sensor FLII12Pglu-700µΔ6. A. H441 cells grown on coverslips were exposed 542 
to either osmotically balanced 5mM glucose; (filled circles) or 15mM glucose(closed 543 
triangles), both n=16.  Cells were also exposed to the same conditions in the presence of the 544 
hexokinase inhibitor BrPy shown as open circles or open triangles respectively (both n=14). 545 
B.  FRET ratio (ECFP/Citrine) for H441 cells grown at air-liquid-interface and exposed to 546 
either 5mM glucose (filled circles, n=12) or 15mM glucose (closed triangles, n=6).  Cells 547 
were also exposed to 5mM in the presence of the hexokinase inhibitor BrPy shown as open 548 
circles (n=4). C. FRET ratio (ECFP/Citrine) in HBEC grown at air-liquid-interface, exposed 549 
to either osmotically balanced 5mM glucose (filled circles, n=12) or 15mM glucose (closed 550 
triangles, n=15) D. FRET ratio (ECFP/Citrine) glucose dose response curve for cells shown 551 
in A, equilibrated with extracellular glucose as described in Results. Data points are shown as 552 
means only in A, B and C for clarity. **** Significantly different p<0.0001 between groups 553 
as indicated. Data in D is shown as mean ± SD Data were fitted with a sigmoidal 1 site 554 
binding curve Df 37, r2 0.6 Values shown in A and B are directly comparable but FRET ratio 555 
values in A, B and C cannot be directly compared because of the different imaging conditions 556 
required for the two cell types and their growth substrates.   557 
 558 
Figure 5. Inhibition of cellular glucose uptake increased FRET ratio indicating a decrease in 559 
intracellular glucose concentration. H441 cells grown at air-liquid interface (ALI) and 560 
exposed to either 5mM glucose or 15mM glucose in the absence or presence of the 561 
facilitative glucose transport inhibitor Cytochalasin B (CytoB). Individual data points are 562 
shown with mean ± SD. **** Significantly different p<0.0001, n=24 between groups as 563 
indicated. 564 
 565 
Figure 6. Intracellular glucose concentration calculated from FRET ratio dose response 566 
curves. A. Calculated intracellular glucose concentration in H441 cells grown on plastic and 567 
exposed to 5mM  (filled circles) or 15mM D-glucose (15mM; hyperglycaemia, closed 568 
triangles) and in the presence of BrPy shown as open circles/open triangles.  Values were 569 
calculated using the dose response curve shown in Figure 1B. Individual data points are 570 
shown with mean ± SD, ****p<0.0001; n=117, between groups as indicated. B. Calculated 571 
intracellular glucose concentration for H441 cells at grown at air-liquid interface in either 572 
5mM glucose (filled circles) or 15mM glucose (closed triangles) or 5mM glucose in the 573 
presence of BrPy (open circles). Individual data points are shown with mean ± SD, 574 
****P<0.0001; n=83 between groups as indicated. C.  Calculated intracellular glucose for 575 
HBEC cultured at air-liquid interface in either 5mM glucose  (filled circles) or 15mM glucose 576 
(closed triangles). Individual data points are shown with mean ± SD, ****P<0.0001; n=150, 577 
between groups as indicated. 578 
 579 
Figure 7.  Glycolysis, glycogen and sorbitol are increased by elevation of extracellular 580 
glucose concentration. A. Glycolysis measured in airway cells as extracellular acidification 581 
rate (ECAR) after injection of 5mM glucose (closed circles) or 15 mM glucose (closed 582 
triangles).  ****P<0.0001; n=34. B. Glycogen measured in airway cells after exposure to 583 
5mM glucose (closed circles) or 15 mM glucose (closed triangles) and BrPy (open symbols).  584 
Individual data points are shown with mean ± SD, ***P<0.001, ****P<0.0001, n=6. C. 585 
Sorbitol measured in airway cells after exposure to 5mM glucose (closed circles) or 15 mM 586 
glucose (closed triangles) and BrPy (open symbols) or epalrestat (EP) (half shaded symbols).  587 
Individual data points are shown with mean ± SD, *P<0.05, **P<0.01, n=8 588 
 589 
Figure 8.  Paracellular diffusion drives ASL glucose concentration. A. Transepithelial 590 
electrical resistance (TEER) and B. Glucose concentration in ASL washes after exposure to 591 
5mM glucose (closed circles) or 15 mM glucose (closed triangles) and BrPy (open symbols).  592 
Individual data points are shown with mean ± SD, ***P<0.001, ****P<0.0001, n=6.  593 
Proposed mechanism for the role of HK2 in maintaining low intracellular glucose in C. 594 
Normoglycaemia and D. Hyperglycaemia.  There is a diffusion gradient for paracellular 595 
movement of glucose from the blood/interstitium to the airway surface liquid (ASL). Glucose 596 
uptake via glucose transporters (GLUT) is maintained by metabolism which generates low 597 
intracellular glucose.  We propose that this occurs predominantly by HKII driven conversion 598 
of glucose to glucose-6-phosphate and glycolysis. When blood glucose levels are raised to 599 
15mM (hyperglycaemia) there is increased paracellular movement of glucose into the ASL. 600 
Increased glucose uptake, elevates HK2 activity at the mitochondria, increasing G-6-P, 601 
glycolysis and glycogen synthesis.  This effectively reduces intracellular glucose 602 
concentration which maintains a glucose gradient for clearance of glucose from the ASL and 603 
prevents transcellular efflux into the ASL. Inhibition of HKII with BrPy elevates intracellular 604 
glucose but concentrations remain low in comparison to external glucose concentration 605 
indicating additional contribution of HKI/III and the HK-independent polyol pathway to 606 
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